Table 1 Baseline characteristics of patient cohort and the different persistent disease activity groups

Females^a,b

293 (76%)

52 (58%)

241 (82%)

102 (78%)

139 (86%)

Age (years)^a,b

56.35 ± 13

51.96 ± 13

57.69 ± 12

55.11 ± 12.31

59.81 ± 11.59

RA duration (years)

9.2 ± 8.6

9.57 ± 10

9.1 ± 8.12

8.71 ± 7.71

9.43 ± 8.45

RA duration < 2 years

70 (18%)

22 (24%)

48 (16%)

20 (15%)

28 (17%)

Seropositive* (n = 217)

100 (46%)

15 (47%)

85 (46%)

37 (51%)

48 (43%)

TJC28* (n = 316)^a,b

10.53 ± 6.5

7.93 ± 6.3

11.14 ± 6.4

9.61 ± 5.56

12.39 ± 6.74

SJC28* (n = 316)^a,b

8.99 ± 6.24

6.17 ± 6.1

9.66 ± 6.1

8.14 ± 5.55

10.89 ± 6.26

ESR* mm/s (n = 256)

38.62 ± 24

35.37 ± 23

39.4 ± 24

37.86 ± 23.42

40.63 ± 25.02

CRP* mg/dl (n = 227)^a

2.57 ± 6

4.07 ± 12

2.22 ± 3.15

2.31 ± 3.32

2.15 ± 3.02

DAS28 (imputed)^b

5.7 ± 0.99

4.92 ± 1

5.94 ± 0.86

5.62 ± 0.74

6.02 ± 0.86

CDAI* (n = 296)^b

33 ± 12.19

26.06 ± 12

34.6 ± 12

30.86 ± 10.05

37.62 ± 12.13

SDAI* (n = 261)^b

35.34 ± 13

29.99 ± 17

36.64 ± 12

32.66 ± 10.44

39.63 ± 12.18

Physician VAS G.* (n = 298)^a,b

69.5 ± 14.8

62.92 ± 16

71.13 ± 14

67.57 ± 15.12

73.97 ± 12.7

Patient VAS G.* (n = 315)^b

66.11 ± 19

59.43 ± 25

67.69 ± 17

63.74 ± 17.82

70.93 ± 15.54

Patient VAS Pain* (n = 302)

67.41 ± 17

62.93 ± 25

68.5 ± 17.2

66.26 ± 18.57

70.38 ± 15.87

HAQ (imputed)^a,b

0.84 ± 0.44

0.63 ± 0.4

0.9 ± 0.5

0.77 ± 0.43

1 ± 0.45

Euroqol* (n = 82)

0.34 ± 0.38

0.36 ± 0.4

0.34 ± 0.39

0.4 ± 0.34

0.26 ± 0.43

Previous csDMARDs

2.34 ± 1.13

2.11 ± 0.9

2.41 ± 1.18

2.34 ± 1.25

2.46 ± 1.11

Ongoing csDMARDs

1.15 ± 0.57

1.15 ± 0.6

1.15 ± 0.6

1.1 ± 0.63

1.19 ± 0.53

Monotherapy ^b

32 (8%)

7 (8%)

25 (9%)

16 (12%)

9 (6%)

Methotrexate

279 (73%)

62 (69%)

217 (74%)

97 (73%)

120 (74%)

Anti-TNF ^b

350 (90%)

88 (98%)

262 (89%)

124 (93%)

138 (85%)

Prednisolone

184 (48%)

44 (49%)

140 (48%)

71 (53%)

69 (43%)